Navigation Links
Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
Date:12/11/2008

sarcoma 9* SD (tumour resection after cycle 4) ------------------------------------------------------------------------- Chordoma 6* SD ------------------------------------------------------------------------- Unspecified Spindle Cell 6* SD ------------------------------------------------------------------------- * patients still on study

"We are very pleased to have met the statistical endpoint in our first U.S. Phase 2 study, particularly in such a difficult-to-treat form of cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "The interim data indicate that REOLYSIN(R) is active in various types of metastatic sarcoma, and that late-stage clinical trials are justified."

Sarcomas are malignant tumors growing from connective tissues, such as cartilage, fat, muscle, or bone. According to the American Cancer Society, only 16.3% of patients with distant spread of sarcoma live longer than five years. There is an unmet medical need for effective treatments for patients with this type of disease.

Clinical Trial Design

The trial (REO 014) is a Phase 2, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days, every 28 days. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Biomatrica, the leader in room,temperature biological sample stabilization, announced ... President of Sales and Marketing.,Biomatrica,s interim Vice President of ... of the company and will continue to serve as,an ... brings fourteen years of sales and marketing experience in,the ...
... operations during the first ... ... in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Atrium Innovations ... for health and nutrition industries, announced today,his financial results for the first ...
... 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that ... Wednesday, May 7, 2008., The Company has scheduled ... on May 7, 2008, at 11:00 AM EDT. Interested ... least,five minutes prior to the call. A replay of ...
Cached Biology Technology:Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2
(Date:4/24/2014)... brain infection caused by fungus could now be treated in ... University of Liverpool scientists. , Cryptococcus a ... relatively neglected in medical research. They are found in ... East Asia and mainly affect people with weakened immune systems. ... The University research team has tested the effects of the ...
(Date:4/24/2014)... largest river turtle in North America, weighing in at ... Now researchers from Florida and the University of Vermont ... but three. , Examining museum specimens and wild turtles, ... reptile. , Once heavily hunted for turtle meat ... Soup in the 1960s the riverine populations have ...
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... Brookhaven National Laboratory, the New York Structural Biology ... atomic crystal structure and functional mechanism of an ... as drugs, industrial chemicals, and toxic compounds from ... help scientists understand how these compounds are eliminated ...
... improve on milk, but animal scientists at the University ... transgenic goats, which carry the gene for an antibacterial ... bacteria in young goats and pigs that were fed ... one day lead to milk that protects infants and ...
... are preparing to stockpile vaccines against H5N1, the strain ... next flu pandemic. But will these vaccines remain effective ... the July 15 issue of The Journal of Infectious ... PhD, Robert G. Webster, PhD, and coworkers at St. ...
Cached Biology News:Scientists take 'snapshots' of enzyme action 2Transgenic goat's milk offers hope for tackling children's intestinal disease 2Transgenic goat's milk offers hope for tackling children's intestinal disease 3Experimental vaccine protects lab animals against several strains of H5N1 2
... through the extracellular matrix (ECM) is an ... cells initiate invasion by adhering to and ... Proteolytic enzymes, such as MMP collagenases, dissolve ... membrane) surrounding the blood vessels to allow ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
... of poor quality running into billions ... are under increasing pressure to reduce ... the microscopic distribution of ingredients is ... such as dissolution, stability, bio-availability and ...
Biology Products: